What is compounded tirzepatide?
Tirzepatide is the active ingredient in Eli Lilly's brand-name products Mounjaro (FDA-approved 2022 for type 2 diabetes) and Zepbound (FDA-approved 2023 for chronic weight management, 2024 for obstructive sleep apnea in obesity). It is a dual GLP-1/GIP receptor agonist with the largest published weight loss effect of any obesity medication (~21% mean weight loss at 72 weeks on 15 mg in SURMOUNT-1).
Compounded tirzepatide is a customized injectable preparation of the same active pharmaceutical ingredient — tirzepatide — manufactured by a licensed compounding pharmacy rather than by Eli Lilly. Compounding pharmacies operate under section 503A (traditional patient-specific compounding) or 503B (outsourcing facilities) of the FD&C Act. They are regulated by state boards of pharmacy and, for 503B facilities, by FDA.
Compounded tirzepatide is not FDA-approved. FDA approves drug products manufactured by drug companies under New Drug Applications; it does not approve compounded preparations. FDA regulates the compounding pharmacy industry — quality standards, inspections, and what may legally be compounded — rather than approving individual compounded medications.
Is compounded tirzepatide legal in 2026?
Short answer: only under specific clinical conditions, after FDA's February 2025 declaration that tirzepatide is no longer in shortage.
The shortage rule
Under section 503A of the FD&C Act, traditional compounding pharmacies cannot compound a drug that is "essentially a copy" of a commercially available FDA-approved drug, except under narrow circumstances. One major exception is when the FDA-approved drug is on the FDA Drug Shortage list — during a shortage, 503A and 503B pharmacies may compound the drug to meet patient needs.
From 2022 through 2024, tirzepatide was on the FDA Drug Shortage list because Eli Lilly's manufacturing could not keep up with demand. This window enabled large-scale compounded tirzepatide production by 503B outsourcing facilities and 503A pharmacies, dispensed through telehealth platforms at a fraction of brand-name cost.
In February 2025, FDA announced that tirzepatide was no longer in shortage. After a court-ordered transition period, the broad compounding exception ended. Compounded tirzepatide is now permitted only when there is a specific clinical need for the individual patient that the commercial product cannot meet — for example, a dose not commercially available, an allergy to a specific excipient in the FDA-approved formulation, or a documented inability to use the commercial product.
What "essentially a copy" means
A compounded preparation that is just a duplicate of the FDA-approved drug in the same strength is generally considered "essentially a copy" and is not permitted under 503A outside of a shortage. A compounded preparation with a meaningful clinical difference for the individual patient — different dose strength, different route, combination with another active ingredient for a documented need — can be permitted, with the prescriber documenting the clinical reason in the medical record.
State-level variation
State boards of pharmacy may add restrictions beyond federal law. A few states have moved to limit compounded GLP-1 medications independent of FDA shortage status. Telehealth providers must operate within state-by-state rules; this is one reason platforms may be available in some states but not others.
What this means for patients
If you are considering compounded tirzepatide through a telehealth service, the platform should be able to explain how the specific compound they will prescribe falls within current FDA and state rules. If a service offers compounded tirzepatide that appears to be a direct copy of brand-name Mounjaro or Zepbound at the same dose, with no clinical rationale documented, that may not be legally compliant.
Get a clear answer on whether you qualify
A licensed clinician can evaluate whether compounded tirzepatide is clinically and legally appropriate for your specific situation.
See If You Qualify →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure
Compounded tirzepatide vs Mounjaro and Zepbound
| Factor | Compounded tirzepatide | Mounjaro / Zepbound (brand-name) |
|---|---|---|
| Active ingredient | Tirzepatide (same as brand-name) | Tirzepatide |
| Manufacturer | Licensed 503A or 503B compounding pharmacy | Eli Lilly |
| FDA approval | Not FDA-approved as a drug product | FDA-approved 2022 (Mounjaro), 2023 (Zepbound) |
| Typical cost | $200-$500/month via telehealth | ~$1,060-$1,100/month list price; coupons available |
| Dose flexibility | Custom doses possible when clinically justified | Fixed strengths: 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Quality controls | USP <797> sterile compounding; varies by pharmacy | GMP manufacturing; FDA-regulated |
| Insurance coverage | Generally not covered; self-pay | Sometimes covered, varies by plan and indication |
| Shipping | Typically by mail with cold chain | Pharmacy pickup or mail-order |
How to get compounded tirzepatide through telehealth
A reputable telehealth pathway looks like this:
- Online medical intake. You complete a detailed health history form covering current and past medications, medical conditions, allergies, weight history, and contraindications (thyroid history, pancreatitis history, pregnancy status).
- Video evaluation with a licensed clinician. A physician, nurse practitioner, or physician assistant licensed in your state reviews your history, may ask follow-up questions, and determines whether tirzepatide is clinically appropriate for you and whether your situation meets the criteria under which a compounded version can be prescribed.
- Laboratory work, where indicated. Some clinicians request baseline labs (HbA1c, lipid panel, comprehensive metabolic panel) before initiation, especially for weight management. Telehealth services typically partner with a lab company for at-home or local draw.
- Prescription and pharmacy dispensing. If approved, your prescription is sent to a partnered compounding pharmacy. The pharmacy prepares your specific compound and ships it to you, typically in cold-chain packaging.
- Follow-up and titration. Most programs include scheduled or as-needed follow-up to manage dose titration and side effects.
Compounded tirzepatide cost
As of 2026, typical pricing for compounded tirzepatide through telehealth is $200-$500 per month, with significant variation by:
- Dose. Higher doses (e.g., 12.5 mg or 15 mg compound) generally cost more than starting doses.
- Provider model. Some platforms bundle clinician visits, lab work, and medication into a flat monthly fee; others charge separately.
- Pharmacy. Different compounding pharmacies have different cost structures.
- Quantity. Three-month supplies often have per-month discounts versus monthly.
Compounded tirzepatide is generally not covered by commercial health insurance because it is not an FDA-approved drug product. Self-pay is the rule. For comparison, brand-name Zepbound's manufacturer-supported price for self-pay (through LillyDirect) has been roughly $349-$499/month for lower vial strengths as of 2026, narrowing the cost gap.
Is compounded tirzepatide safe?
Safety of compounded tirzepatide depends heavily on the compounding pharmacy. The active ingredient is the same as brand-name tirzepatide, so the pharmacologic risk profile (GI side effects, pancreatitis warning, gallbladder, thyroid C-cell boxed warning) carries over. Additional considerations specific to compounded preparations:
Pharmacy quality indicators to look for
- Licensure. Active state board of pharmacy license in good standing.
- 503A vs 503B. 503A pharmacies serve individual patient prescriptions; 503B outsourcing facilities have FDA oversight and additional GMP requirements.
- USP <797> compliance. The US Pharmacopeia standard for sterile compounding. Reputable pharmacies maintain certification.
- Third-party testing. Independent verification of potency, sterility, and absence of contaminants. Ask whether the pharmacy provides certificates of analysis.
- API sourcing. Tirzepatide API should be sourced from FDA-registered facilities. Be cautious of pharmacies that cannot or will not document API origin.
- Cold chain shipping. Tirzepatide requires refrigeration. Properly insulated shipping with temperature monitoring matters.
FDA warnings about unsafe compounded GLP-1
FDA has issued multiple warning letters and consumer alerts about unsafe compounded semaglutide and tirzepatide products, including some that contained the salt form (semaglutide sodium, etc.) rather than the base form used in approved products. The salt forms have not been studied for safety or efficacy in this context. Stick to providers and pharmacies that document use of the base form.
Side effects of compounded tirzepatide
The side effect profile is the same as brand-name tirzepatide because the active ingredient is identical:
- Common: nausea, vomiting, diarrhea, constipation, abdominal pain.
- Uncommon but serious: pancreatitis, gallbladder disease, kidney injury, severe gastroparesis.
- Boxed warning: thyroid C-cell tumors (rodent data) — contraindicated in personal or family history of MTC or MEN-2.
See our complete side effects guide for details.
What about compounded tirzepatide tablets?
Some compounding pharmacies prepare oral tirzepatide formulations marketed as a needle-free alternative. Important context:
- Tirzepatide is a peptide. Oral bioavailability of peptides is generally low (often well under 1% without specialized absorption technology).
- FDA-approved oral GLP-1 medication exists only for semaglutide (Rybelsus), which uses a specific absorption enhancer (SNAC).
- No FDA-approved oral tirzepatide product exists.
- Compounded oral tirzepatide does not have published clinical trial data demonstrating equivalent efficacy to injectable tirzepatide.
If a service is selling compounded oral tirzepatide tablets and claiming equivalence to Mounjaro or Zepbound, ask for the underlying pharmacokinetic and clinical data. Lack of an answer is informative.
Should you consider compounded tirzepatide?
Compounded tirzepatide can be a reasonable option when:
- You meet clinical eligibility criteria (BMI ≥30, or ≥27 with a weight-related comorbidity; or T2D), and
- Brand-name Mounjaro or Zepbound is unaffordable for your situation, and
- A licensed clinician determines that a compounded preparation is appropriate under current legal rules, and
- The compounding pharmacy meets the quality indicators described above.
Compounded tirzepatide is not appropriate when brand-name is accessible at a comparable cost, when the compounded preparation appears to be a direct copy of brand-name without clinical justification, when the pharmacy cannot document API sourcing and quality controls, or when contraindications exist.
This is a decision best made with a licensed clinician who knows your specific medical history and the current legal landscape in your state.
See if compounded tirzepatide is right for you
A licensed clinician via telehealth can evaluate your eligibility and discuss whether brand-name or legally compounded options are appropriate.
Check Your Eligibility →Sponsored link. We earn a commission when you sign up. Medical eligibility determined by licensed providers. Disclosure